Assay Service for assessing ADME properties and in vivo PK properties with the selected vendor. ENAMINE US INC

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH OLAO

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N98026Q01193ENAMINEUSINCPCANIAAA08396

NAICS

424690 - Other Chemical and Allied Products Merchant Wholesalers

Classification Code

6505

Additional Details
Set Aside

NONE

Place of Performance

Bethesda, Maryland, UNITED STATES

SourceSAM
Documents1
The National Institutes of Health (NIH), Office of Logistics and Acquisition Operations (OLAO), has issued a combined synopsis/solicitation for specialized assay services to support the Section on Medicinal Chemistry (SMC) in Bethesda, Maryland. This procurement seeks to engage a qualified vendor—specifically ENAMINE US INC—to conduct comprehensive assessments of absorption, distribution, metabolism, and excretion (ADME) properties, as well as in vivo pharmacokinetic (PK) studies, for novel molecular entities under development for metabolic and alcohol-associated diseases. The primary objective of this procurement is to facilitate the translational evaluation of new chemical compounds by employing a suite of derisking assays. These include both in vitro (cell-based) and in vivo (animal-based) methodologies. A key component of the requested services is the Caco-2 Permeability Assay, a well-established in vitro model that closely simulates the human intestinal epithelium. This assay is critical for predicting the oral absorption potential of candidate compounds, providing essential data on passive diffusion, active transport, and efflux mechanisms—particularly those mediated by P-glycoprotein (P-gp). The insights gained from these studies are vital for informing structure-activity relationship (SAR) optimization, enhancing compound permeability, and mitigating transporter-related liabilities that could compromise bioavailability. Additionally, the scope of work includes conducting pharmacokinetic studies in C57BL6 mice to further characterize the in vivo behavior of the compounds. The integration of these assays is intended to generate robust data sets that will guide decision-making regarding the advancement of compounds into further stages of development. The procurement is classified under NAICS code 424690 (Other Chemical and Allied Products Merchant Wholesalers, 2022 version) and Product Service Code 6505. There are no set-aside restrictions associated with this opportunity, making it open to all qualified vendors. The place of performance is specified as Bethesda, Maryland, United States. The contracting entity for this requirement is the National Institutes of Health, under the Department of Health and Human Services. The primary point of contact for this solicitation is Vishnuvajjala Hanumanth Rao, who can be reached via email at [email protected]. This opportunity was posted on September 18, 2026, with a response deadline of September 19, 2026. Interested parties are encouraged to review the full notice and any associated attachments via the provided SAM.gov link: https://sam.gov/opp/33f918c6716e4e99852469db864962f0/view. Contractors considering this opportunity should have demonstrated expertise in chemical reagent assay development, laboratory testing services, and the execution of both in vitro and in vivo ADME/PK studies, particularly those involving Caco-2 permeability assays and murine pharmacokinetic models. The ability to generate high-quality, decision-enabling data for early-stage drug development is essential for successful performance under this contract.